Insider Transactions Reported by 11 Insiders of GT Biopharma, Inc.

Symbol
GTBP on Nasdaq
Location
San Francisco, CA

There are no Buy or Sell transactions made by insiders since 18 Mar 2025

GT Biopharma, Inc. executives and other stock owners filed with the SEC include:

Name Relationship Holdings Value Past Year Net Change Change % Report Date
Manu Ohri CFO & Secretary $100,450 11 Aug 2023
Gregory Berk Pres. of R&D, CMO 15 Jul 2022
Michael Martin Breen CEO and Director, Director 04 Sep 2025
Andrew J. Ritter Director 08 May 2025
Bruce Wendel Director 27 Jan 2023
Rajesh C. Shrotriya MD Director 27 Jan 2023
Gavin Choy Acting Chief Financial Officer 31 Dec 2021
Charles J. Casamento Director 04 Sep 2025
Hilary Kramer Director 04 Sep 2025
Alan Louis Urban Chief Financial Officer 04 Sep 2025
David C. Mun-Gavin Director 04 Sep 2025

Recent Insider Transactions by Companies or Individuals for GT Biopharma, Inc.

Showing up to 300 most recent insider transactions from the last 12 months.

Insider Symbol Class Transaction % Value $ * Price $ Shares Shares Owned Date Ownership
David C. Mun-Gavin GTBP Option to purchase Common Stock Award 31,250 31,250 04 Sep 2025 Direct
Michael Martin Breen GTBP Option to purchase Common Stock Award 300,000 100,000 04 Sep 2025 Direct
Alan Louis Urban GTBP Option to purchase Common Stock Award 100,000 50,000 04 Sep 2025 Direct
Charles J. Casamento GTBP Option to purchase Common Stock Award 62,500 62,500 04 Sep 2025 Direct
Hilary Kramer GTBP Option to purchase Common Stock Award 31,250 31,250 04 Sep 2025 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.